AI Article Synopsis
- The study aimed to evaluate the reliability and validity of the Lower Extremity Motor Activity Log (LE-MAL) for measuring lower extremity use in adults with multiple sclerosis (MS).
- Conducted with 43 participants through telephone evaluations, it involved administering the LE-MAL twice, along with other measures during the first call.
- Results showed high test-retest reliability (intraclass correlation >0.94) and strong correlations with other mobility scales, indicating that LE-MAL is a dependable tool for assessing lower extremity use in this population.
Article Abstract
Objectives: To determine the test-retest reliability and validity of the Lower Extremity Motor Activity Log (LE-MAL) for assessing LE use in the community in adults with multiple sclerosis (MS).
Design: Prospective analysis of measures conducted by trained examiners.
Setting: Participants were evaluated by telephone on several measures of LE use.
Participants: Adults with MS (N=43).
Interventions: Not applicable.
Main Outcome Measures: The LE-MAL has 3 subscales (Assistance, Functional Performance, and Confidence). It was administered twice, at least 2 weeks apart. The Multiple Sclerosis Walking Scale (MSWS-12), Patient Determined Disease Steps (PDDS), and Mobility Scale were only administered during the first call.
Results: The test-retest reliability of the composite and the 3 subscale LE-MAL scores were high (intraclass correlation, >0.94). The composite and subscale LE-MAL scores were strongly correlated with the MSWS-12, PDDS, and Mobility Scale scores (r=-0.56 to -0.77; P<.001).
Conclusion: This initial study suggests that the LE-MAL reliably and validly measures LE use in the community in adults with MS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apmr.2020.10.125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report.
Int J Rheum Dis
December 2024
Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ocrelizumab is a humanized monoclonal antibody, which acts as an anti-CD20 antibody. It is used as a treatment of both relapsing-remitting multiple sclerosis (RRMS) and Progressive types. The aim of this study is to report the first patient with alopecia universalis after switching from rituximab to ocrelizumab.
View Article and Find Full Text PDFInterleukin in Immune-Mediated Diseases: An Updated Review.
Mol Biotechnol
December 2024
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan.
The immune system comprises various regulators and effectors that elicit immune responses against various attacks on the body. The pathogenesis of autoimmune diseases is derived from the deregulated expression of cytokines, the major regulators of the immune system. Among cytokines, interleukins have a major influence on immune-mediated diseases.
View Article and Find Full Text PDFReassuring Insights Into the Effect of COVID-19 on Symptoms and Disability in People With Multiple Sclerosis: Weathering the Storm.
Neurology
January 2025
Dipartimento di Scienze della Salute, Università degli Studi di Genova, Genoa, Italy.
Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
Neurology
January 2025
Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco.
Background And Objective: The impact of menopause on the brain is not well understood. Hormonal changes, including puberty and pregnancy, influence the onset and course of multiple sclerosis (MS). After menopause, a worsening of MS disease trajectory measured on the clinician-rated Expanded Disability Status Scale (EDSS) was reported in some, but not all, studies.
View Article and Find Full Text PDFEffects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
Neurology
January 2025
Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba.
Background And Objectives: Infections, including infection with SARS-CoV-2 (COVID-19), could alter the course of multiple sclerosis (MS). Previous studies assessing the effects of COVID-19 on MS outcomes were small and had discordant findings. The study objective was to evaluate the association of COVID-19 infection with changes in the trajectory of MS symptoms and disability.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!